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Background: Keratinocytic epidermal nevus syndrome (KENS) is a complex disorder not only characterized by the
presence of epidermal nevi but also by abnormalities in the internal organ systems. A small number of cases with
KENS are molecularly characterized and reported in the literature with somatic activating RAS, FGFR3 and PIK3CA
mutations.
Case presentation: In this study we present a patient with hyper- and hypopigmented regions, verrucous
pigmented skin lesions and a paravertebral conglomerate tumour at the level of the cervical and thoracic
spine. A large lipomatous dumbbell tumour caused atrophy of the spinal cord with progressive paraparesis.
We identified a mosaic c.35G > A (p.Gly12Asp) KRAS mutation in the pigmented verrucous epidermal nevus
tissue, the intraneural schwann cells and the lipoma. The c.35G > A (p.Gly12Asp) KRAS mutation was absent
in the peripheral blood leukocytes.
Conclusion: We conclude that KENS, the intraneural Schwann cell proliferation and the lipoma in this
individual were caused by a postzygotic and mosaic activating c.35G > A (p.Gly12Asp) KRAS mutation.
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Ras proteins play a crucial role in cellular growth factor sig-
naling. RAS mutations, found in 30% of human tumours,
have an activating effect on the protein, are oncogenic and
activate a number of downstream pathways [1].
Non-organoid keratinocytic epidermal nevus (KEN) is
characterized by benign congenital hyperpigmented skin
lesions following Blaschko’s lines. Epidermal nevi with
localized epidermal thickening are present at birth or be-
come visible during early childhood. KEN in association
with extracutaneous lesions in brain, muscular skeleton or
eye is defined as keratinocytic epidermal nevus syndrome
(KENS). Neurological abnormalities can include sei-
zures, cognitive impairment, developmental delay and* Correspondence: v.mautner@uke.uni-hamburg.de
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unless otherwise stated.hemiparesis. Potential skeletal abnormalities are abnormal
curvature of the spine and incomplete bone formation.
Mosaic FGFR3, PIK3CA and RAS mutations are rec-
ognized in KEN with HRAS as the most prevalent mu-
tated gene [2-4]. RAS mutations are reported in mosaic
RASopathies i.e. non-organoid KEN, sebaceous nevus and
in extra-cutaneous manifestations of the corresponding
syndromes, KENS and Schimmelpenning syndrome [5,6].
Only a few patients with epidermal nevus syndrome are
molecularly characterized. In the context of understanding
the phenotype-genotype in RASopathies, especially in epi-
dermal nevus, we describe a patient with hyperpigmenta-
tion and severe neuroskeletal abnormalities.Case presentation
The patient was born by Caesarean section (weight
3760 g, length 55 cm) and developed normal speech,
while motor development was delayed (free sitting at
12 months, back to belly turn at 13 months, pulling intotral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 3T-MRI of the upper spine: T1 weighted sagittal image showing a large cervical and thoracic tumour mass (a). T2 weighted
sequences (b) detect extensive intraspinal tumour formations, partially fat-isointense on fat-suppressed sequences (c). Transversal T2-images show
the dimensions of the paravertebral mass (d).
Figure 2 Clinical findings of the skin by follow-up presentation: Large inhomogeneous hyper-and hypopigmentation of the upper
extremities (a) and the trunk (b) with serrated and polycyclic borders. Verruceal corneated mass on the upper back with tongue
shaped tails and granular surface; median scar from precious neurosurgical intervention (c).
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tient developed pain in the left arm as well as progressive
paraparesis. Surgical removal of compressive intraspinal,
extramedullar components of a tumour was performed at
the age of 4 years with tumour reduction and partial relief
of symptoms.
At 14 and 16 years of age follow up MRI demonstrated
a large paravertebral conglomerate tumour next to the
cervical and thoracic spine with extensive additional
intraspinal components (Figure 1a-d). Consecutively, there
was severe narrowing of the spinal canal with spinal cord
compression. The intraspinal tumour was a long cylin-
drical, inhomogeneously configured mass, which filled
the spinal canal incompletely from C3 to T1. In addition,
there was a remarkably large intraspinal lipoma located
between C5 to C7, which showed typical bright pillow-like
tissue (fat isointense on T1 weighted imaging) present-
ing dark in T2-weighted fat suppressed sequences. TheFigure 3 Hypertrophic changes in a nerve root located within a cong
fascicles with extensive onion bulb formation by S-100-protein expressing
middle and right, neurofilament detection in a neuron and axons in the cespinal nerves (C3-T1) on both sides showed cylindrical or
dumbbell-like thickening with intraspinal expansion, so
that the spinal cord was compressed from the right side
below C3. Consecutively, there was atrophy of the spinal
cord below segment T2. Additionally a right convex
thoracolumbar scoliosis was found. Cranial MRI showed
no abnormalities. Ophthalmologic examination showed
bilateral impaired vision (50%) and astigmatism with no
Lisch nodules or other abnormalities.
At follow-up at 17 years of age he showed a large hyper-
pigmentation and hypopigmentation of upper body parts
ranging from the trunk to the arms. There was partly
polycyclic/polygonal hyperpigmentation of chest and back
(Figure 2a,b), more pronounced on the left. An interscap-
ular large segmented dark hyperpigmentation area with a
verruccal epidermal nevus of about 20 × 10 cm and 15 ×
3 cm was present (Figure 2c). The hyperkeratotic surface
was partially fissured and the patches sharply bordered.lomerate tumor. Upper row, nerve root with hypertrophic nerve
schwann cells; lower row, left, lack of EMA expression in the tissue;
nter of onion bulbs.
Figure 4 Sanger sequences showing the c.35G > A (p.Gly12Asp)
mutation (in yellow) in the KRAS gene in the skin sample, in
the tumor sample with concentric intraneural Schwann cell
proliferation and in the lipoma sample. This mutation was not
present in the blood sample from the patient.
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cion upon a genetic disorder and the tentative diagnosis of
Neurofibromatosis type 1 was made.
Neurological examination showed mild talipes equino-
varus and slow progressive incomplete paraparesis of the
legs with increased muscle tonus and spasticity. There was
a positive Babinski reflex (pyramidal sign) and a missing
cremaster- and sphincter ani reflex. Cranial nerve dysfunc-
tion was not seen. Since there was chronic slow progres-
sive weakness of finger extension of digits III-V of the left
hand, grabbing is only possible with digit I and II. To date
there is still progressive transversal spinal cord syndrome
with spasticity, paraparesis and pain. The patient is wheel
chair bound and only can stand upright with assistance.
The patient has a proximal neuropathy and no evidence
for a distal neuropathy, since electromyography analysis is
normal. Recent whole body MRI and DXA showed osteo-
penia, although normal FGF23 and low vitamin D levels
were present in the blood sample of this individual.
At age 4 after tumor removal histology was performed
of skin (verruca), intraneural tissue and lipoma tissue.
Materials and methods
Immunohistochemistry
For routine diagnostics an H&E staining was performed
on 4 μm thick sections from formalin-fixed, paraffin-
embedded (FFPE) tissue. For immunohistochemical la-
belling sections from FFPE tissue were pretreated and
incubated with primary antibodies against S-100-protein
(DAKO, Hamburg, Germany, # Z 0311, 1:8000), epithe-
lial membrane antigen (EMA, DAKO, # M 0613, 1:200)
and neurofilament (DAKO, # M0762, 1:800) in an auto-
mated stainer (Ventana Medical Systems, Tucson, AZ,
USA) according to standard protocols. As detection was
the peroxidase method used with diaminobenzidine as
chromogen (Ultraview DAB, 760–500, Ventana).
Mutation analysis
The DNA was extracted from blood and three FFPE tissue
samples (verrucous skin, intraneural perineurioma and
lipoma) by use of standard techniques. All DNA sam-
ples were screened for the following RAS and PIK3CAmu-
tations: c.37G > C (p.Gly13Arg) in HRAS (NM_005343.2)
and c.35G >A (p.Gly12Asp) in KRAS (NM_004985.3) and
c.1258 T >C (p.Cys420Arg), c.1624G >A (p.Glu542Lys) and
c.3140A >G (p.His1047Arg) in PIK3CA (NM_006218.2). In
total, 5 primer pairs were designed to maximum amplify
the corresponding fragments of 300 bp (primer sequences
available on request). All primers were tagged with M13
sequences to facilitate sequencing. The PCR products
were bidirectionally Sanger sequenced and run on an ABI
sequencer.
All procedures performed were in accordance with the
Declaration of Helsinki.Results
Histological sections of the three samples showed a typ-
ical lipoma and skin with hyperplasia confirming verru-
cous epidermal hyperplasia. In the nerve tissue ganglion
cells and spindle shaped cells arranged in concentric pat-
terns were observed resembling a perineurioma or onion
bulb formation, morphologically not consistent with a
schwannoma or neurofibroma. There was no nuclear
atypia and no mitoses.
Upon immunohistochemical labelling with antibodies
against S100 protein, neurofilament and EMA, the
onion bulb structures were strongly positive for S-100-
protein (Figure 3 upper row) and commonly contained a
neurofilament-positive central axon (Figure 3 lower row).
No EMA expression was detected (Figure 3).
Previously, neurofibromatosis type 1 was clinically and
genetically ruled out. None of the specific mutations in the
HRAS or PIK3CA genes were found in the DNA extracted
from the three tissue samples. However, in all three sam-
ples the c.35G >A (p.Gly12Asp) missense mutation in the
KRAS gene was detected. The c.35G >A (p.Gly12Asp) mu-
tation in KRAS was in all three samples present in a het-
erozygous state (Figure 4), with an average allele frequency
of 44% in the hyperpigmented verrucous skin sample, 49%
in the tumor sample with the concentric intraneural
Schwann cell proliferation and 56% in the lipoma sample
Table 1 Clinical characteristics of patients with KENS in the literature
Case (reference) 1 [9] 2 [10] 3 [11] 4 [12] 5 [13] 6 [14] 7 [15] 8 [8]
Age at presentation
(years)
Newborn 19 14 17 12 5 Newborn 21
Sex F M M F F F F M
Clinical features EN following lines
of Blaschko,
rhabdomyosarcoma,
micropolycystic
kidneys and growth
retardation
EN, urothelial-cell
carcinoma of the
bladder
Multiple EN,
hypotonia of the right
arm, thymoma, cystic
lesions in hand and
cervical bones
Systemic EN
following the lines
of Blaschko sharply
bounded by
ventral midline,
scoliosis
Extensive EN
and mild facial
dysmorphy
Systematized EN,
seizures, delayed
language and
psychomotor
development,
brain abnormalities
Verrucous
hyperpigmented
streaks sharply
demarcated at
midline, seizures and
brain abnormalities
(6 months)
Multiple EN,
multiple spinal
tumors, lipoma,
duplic renal
arteries, ectasia of
aorta, scoliosis
Gene mutation KRAS HRAS HRAS FGFR3 FGFR3 FGFR3 FGFR3 PIK3CA
c.35G > A
(p.Gly12Asp)
c.34G > A
(p.Gly12Ser)
c.37G > C
(p.Gly13Arg)
c.742C > T
(p.Arg248Cys)
c.742C > T (p.
Arg248Cys)
c.742C > T
(p.Arg248Cys)
c.746C > G
(p.Ser249Cys)
c.3140A > T
(p.His1047Leu)
Tissue investigated:
-carrying mutation Epidermal
component EN,
rhabodmyosarcoma
Epidermal nevus,
3 urothelial-cell
carcinomas, lung
metastasis, normal
lung tissue, blood
leukocytes and
non-malignant
urothelium
Both EN and
thymoma
EN, oral mucosa
and leucocytes
Verrucous EN EN, blood
leucocytes
EN, the unaffected
skin, urothelial cells
Spinal tissue
(neurofibromas)
-mutation absent Dermal component
EN, normal skin,
blood
Bladder-muscle
layer, 2 cutaneous
angiomas
Lymphocytes Hair roots, normal
skin
Blood, buccal
brushings, hair
roots
Normal skin Blood leucocytes Dermis (posterior
thoracic region)
EN: epidermal nevus; F: female; m: male.
Farschtschiet
al.BM
C
M
edicalG
enetics
 (2015) 16:6 
Page
5
of
7
Farschtschi et al. BMC Medical Genetics  (2015) 16:6 Page 6 of 7based on peak height of both nucleotides at position 35.
No c.35G >A (p.Gly12Asp) mutation in the KRAS gene
was detected in DNA extracted from peripheral white
blood cells from the patient.
Discussion
The dermatological features of the reported patient are
in accordance with the phenotype of previously de-
scribed patients with KENS. The patient in this study
presented with hyper- and hypopigmented regions and
with verrucous hyperpigmented skin lesions. In addition
a paravertebral conglomerate tumour was present next
to the cervical and thoracic spine with a large intraspinal
lipoma causing compression and atrophy of the spinal
cord with progressive paraparesis. It is the first time that
a myelopathy/proximal neuropathy in combination with
the presence of a lipoma is reported in KENS. Further
we could identify Schwann cell proliferation within the
nerve resembling onion bulb formation, however, a typ-
ical schwannoma, as described by Bertola et al. 2012 in a
patient with a germline KRAS (p.Lys5Glu) mutation [7],
was not demonstrated. Recently epidermal nevus syndrome
was described in a patient with an intra-spinal lipoma and
cervical root neurofibromas [8]. In the same paper a further
case had MRI changes suggestive for lumbo-sacral nerve
root tumours which were asymptomatic. This patient was
clinically diagnosed with CLOVES syndrome without co-
occuring epidermal nevi.
We identified the same c.35G > A (p.Gly12Asp) KRAS
mutation in the hyperpigmented verrucous skin tissue,
intraneural perineurioma and lipoma. This mutation was
not detected in the corresponding leukocytes of the
same patient. The data confirm the diagnosis of KENS
as a mosaic RASopathy. This mutation has not been re-
ported as a germline mutation in individuals with Noonan
or CFC syndrome and the clinical phenotype is distinctive
compared to these syndromes. The c.35G >A (p.Gly12Asp)
KRAS mutation has extensively been reported in tumour
tissue described in the open access database COSMIC
(Catalogue Of Somatic Mutations In Cancer) suggesting its
strong oncogenic character. COSMIC contains information
on publications, samples and mutations in cancer tissues.
Codon 12 is the most frequently mutated codon of KRAS
in malignancies. The c.35G >A (p.Gly12Asp) KRAS muta-
tion has been identified frequently in cancers from colon,
pancreas, lung, biliary tract and ovary.
To date, only 8 cases were diagnosed with KENS, mo-
lecularly characterized and their data are summarized in
Table 1 [8-15]. Three males and 5 females were diagnosed
with KENS and the age of presentation varied between new-
born and 21 years. The epidermal nevus can be extensive,
multiple epidermal nevi can be present or the nevus can be
bounded by the ventral midline. The other clinical symp-
toms can differ between individuals and can potentially bevery severe (brain abnormalities, benign and malignant
tumours). Six different somatic mutations were identi-
fied in KENS with pathogenic mutations in the KRAS
(c.35G>A), HRAS (c.34G>A, c.37G>C), FGFR3 (c.742C>T,
c.746C >G) and PIK3CA (c.3140A > T) genes. The epider-
mal nevus was molecularly investigated in 7/8 cases
resulting in the identification of the responsible mutation.
Leucocytes are often tested, but the mutation is frequently
absent. Data for other tissues are variable as well as the
percentage of mosaicism.
Conclusion
KENS patients are still young when the first potential
complications occur. Therefore, it is important that pa-
tients are diagnosed as early as possible to provide a better
multidisciplinary follow up and therapy when needed. If
patients are diagnosed with epidermal nevi and a patho-
genic KRAS, PIK3CA or FGFR3 mutation, they should
undergo further medical examination and potentially also
further imaging (MRI) to identify the extent of disease.
Mosaicism may delay diagnosis and complicate clinical
management of such cases, as genetic confirmation of dis-
ease depends on appropriate tissue sampling.
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